News
![UFC: The Story of a Corporate Turnaround: https://g.foolcdn.com/editorial/images/736799/mfm_20230618.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVU3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3e2726d0bbdc223d8bf776a388b12b38134ce747/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mfm_20230618.jpg?locale=us)
UFC: The Story of a Corporate Turnaround
Michael Thomsen is the author of Cage Kings: How an Unlikely Group of Moguls, Champions, and Hustlers Transformed the UFC Into a $10 Billion Industry.
Motley Fool host Ricky Mulvey caught up with
![3 Monster Stocks in the Making to Buy Right Now: https://g.foolcdn.com/editorial/images/737213/smiling-man-holding-fist-up.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0k3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dec4c57e599bf0f2317c91f949ef648693f7cbc7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/smiling-man-holding-fist-up.jpg?locale=us)
3 Monster Stocks in the Making to Buy Right Now
What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be
![1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever: https://g.foolcdn.com/editorial/images/736693/man-with-arms-behind-head-looking-at-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTg2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b6f9828d2a253ca7bfedb8eaac7967720f5094e1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/man-with-arms-behind-head-looking-at-laptop.jpg?locale=us)
1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever
What's the biggest knock against many high-yield dividend stocks? Probably that either the dividend or the share price is likely to sink sooner or later. That means that you often won't want to own
![Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?: https://g.foolcdn.com/editorial/images/737372/doctor-explains-paper-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDg2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0918e1b25af170f6ce766c3af95af264e06d1c14/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-explains-paper-to-patient.jpg?locale=us)
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
Sometimes even the professionals put the horse before the cart. For instance, Wall Street analysts are currently predicting that shares of the gene editing therapy biotech Intellia Therapeutics
![Why Shares of Abcam Are Jumping Friday: https://g.foolcdn.com/editorial/images/737414/healthcare-lab-treatment-research-scientist-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG82YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--84cdfd406fd316bebf0e049a77403a7364a80713/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist-1.jpg?locale=us)
Why Shares of Abcam Are Jumping Friday
Shares of life sciences company Abcam (NASDAQ: ABCM) were up 13.7% Friday afternoon after rising more than 14.6% earlier in the day. The impetus for the rise was the company's board of directors
![Why Shares of CureVac Jumped This Week: https://g.foolcdn.com/editorial/images/737369/vaccine-injection-doctor-health-check-up.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemc2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3b2cf960f507bfd5581854aee6bfd4f201cb588e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vaccine-injection-doctor-health-check-up.jpg?locale=us)
Why Shares of CureVac Jumped This Week
Shares of CureVac (NASDAQ: CVAC) were up by 14.3% for the week as of Friday morning, after having been up by as much as 16%, according to data provided by S&P Global Market Intelligence. The
![Why Shares of Surmodics Jumped This Week: https://g.foolcdn.com/editorial/images/737353/physicians-in-a-hospital-operating-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG82YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--25a791ac632e7e9c01462fdf7f53a95fbc9474e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physicians-in-a-hospital-operating-room.jpg?locale=us)
Why Shares of Surmodics Jumped This Week
Shares of Surmodics (NASDAQ: SRDX) were up by 24.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The medical device company's stock closed last
![2 Stocks Defying Friday's Market Downturn: https://g.foolcdn.com/editorial/images/737343/car-dealer-gettyimages-507083090.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd002YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6f604186689595208886eec407053a1e24927987/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/car-dealer-gettyimages-507083090.jpg?locale=us)
2 Stocks Defying Friday's Market Downturn
Stock markets have performed well over the past few months, but Wall Street wasn't able to keep the upward momentum going this week. On Friday morning, major market benchmarks opened lower, with
![Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?: https://g.foolcdn.com/editorial/images/736733/a-group-of-business-people-talking-outside.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3c1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dabd3026a84bc83dac53547a69767d38354ea175/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-group-of-business-people-talking-outside.jpg?locale=us)
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Is AstraZeneca a Top Stock to Buy Right Now?: https://g.foolcdn.com/editorial/images/737212/pills-dollar-symbol.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeDA1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc5463a487b33f7167c22ef2670e62812d43b0a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pills-dollar-symbol.jpg?locale=us)
Is AstraZeneca a Top Stock to Buy Right Now?
Dividend-paying pharmaceutical stocks have a rich tradition of delivering market-beating returns on capital. An aging global population, the expansion of healthcare coverage under the Affordable
![Why Dice Therapeutics Stock Bolted Higher This Week: https://g.foolcdn.com/assets/images/fool/tmf-logo_400x400.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaTRFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--7b1053a3605f66e35a9c178293b2594f08cb4204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tmf-logo_400x400.png?locale=us)
Why Dice Therapeutics Stock Bolted Higher This Week
Shares of clinical-stage biotech Dice Therapeutics (NASDAQ: DICE) jumped by 37.5% during the first three and a half days of trading this week, according to data provided by S&P Global Market
![Why Roivant Sciences Stock Is Perking Up Today: https://g.foolcdn.com/editorial/images/737199/growth-chart.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0E0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4dcc6de8ed02c4000f2b7309d896ce8cd731eeca/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth-chart.jpg?locale=us)
Why Roivant Sciences Stock Is Perking Up Today
Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data
![I'm Buying These 3 Resilient Stocks During a Bear Market: https://g.foolcdn.com/editorial/images/736846/scientists-examine-cell-make-up-microscope-biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHM0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a63f277ccd696460c07bc6ff42dfa954ce8f9aed/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-examine-cell-make-up-microscope-biotech.jpg?locale=us)
I'm Buying These 3 Resilient Stocks During a Bear Market
There is a difference of opinion about whether the economy is headed for a recession or perhaps already coming out of one, depending on what metrics are used. That can be confusing for investors
![Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/735727/doctor-smiling-and-holding-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjQ0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--eb4456fb78f966b168e48e5d3b6866b5a23d8005/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-smiling-and-holding-patients-hand.jpg?locale=us)
Is Pfizer Stock a Buy Now?
A year ago, Pfizer (NYSE: PFE) was soundly beating the market, racking up highly impressive sales thanks to its COVID-19 products. But with the pandemic no longer a global health crisis per guidance
![2 No-Brainer Healthcare Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/736530/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFk0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8e4ea1a899ac914c59afe3c38aa901913502148a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=us)
2 No-Brainer Healthcare Stocks to Buy Right Now
Investors looking to participate in the stock market have a multitude of options, and it can sometimes be hard to separate the wheat from the chaff. But some companies look especially attractive
![AT&T Sees Slowing Subscriber Growth but Plenty of Free Cash Flow: https://g.foolcdn.com/editorial/images/737127/money-bag-on-a-pile-of-cash.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd280YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--84f6133a85db269a93874e6511425370796679e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/money-bag-on-a-pile-of-cash.jpg?locale=us)
AT&T Sees Slowing Subscriber Growth but Plenty of Free Cash Flow
AT&T (NYSE: T) CFO Pascal Desroches gave investors a variety of updates while speaking at a technology, media, and telecommunications conference earlier this week. The message was mixed overall. The
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Alleged Industrial Espionage Makes an Interesting Story: https://g.foolcdn.com/editorial/images/736757/mfm_20230615.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzQzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7c57c1ee9853db09bec0132f800623bcc1191c1c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mfm_20230615.jpg?locale=us)
Alleged Industrial Espionage Makes an Interesting Story
In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at
![Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?: https://g.foolcdn.com/editorial/images/736669/investor-considers-papers-at-a-cafe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzAzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6eb2c0d4e6abadab656d47efd46ffc1f341449ee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-papers-at-a-cafe.jpg?locale=us)
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
Over the last couple of weeks, Cathie Wood's ARK Innovation ETF has been busy buying shares of gene-editing biotech Intellia Therapeutics (NASDAQ: NTLA). She's also been selling some shares of
![History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/733946/veterinarian-works-with-dog.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeE0zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d36c5845434749166d5524478e699c4d4f3d0282/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/veterinarian-works-with-dog.jpg?locale=us)
History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever
Over time, stocks with growing dividends and high returns on invested capital (ROICs) have tended to outperform their peers. By highlighting these qualities -- plus a payout ratio below 50% --
![Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030: https://g.foolcdn.com/editorial/images/736672/two-investors-look-at-figures.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFUyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6c3b65fe46fb2d76e9b4e7c7d7041b23f7e27874/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-look-at-figures.jpg?locale=us)
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Is CRISPR Therapeutics Stock a Buy Now?: https://g.foolcdn.com/editorial/images/736895/gettyimages-1096502340.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMU0yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76070af6088685011d8669b9d452c64cbce85e31/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1096502340.jpg?locale=us)
Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration
![Why Shares of Vera Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/736985/radiologist-of-oncology-institute-is-examing-mri-scans.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWsyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc35a5f92766b15851792a411ac4d6a1882cab5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/radiologist-of-oncology-institute-is-examing-mri-scans.jpg?locale=us)
Why Shares of Vera Therapeutics Jumped Tuesday
Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one